15.95

3.82% +0.59

Alx Oncology Holdings Inc (ALXO)

Overview News Price History Option Chain Financials Discussions Forecast

Alx Oncology Holdings Inc stock is currently priced at $15.95, with a 24-hour trading volume of 469.19K. It has seen a +3.82% increased in the last 24 hours and a +30.39% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $15.90 pivot point. If it approaches the $16.59 resistance level, significant changes may occur.

Previous Close:

$15.36

Open:

$15.55

24h Volume:

469.19K

Market Cap:

$807.98M

Revenue:

Net Income/Loss:

$-160.81M

P/E Ratio:

-4.9844

EPS:

-3.2

Net Cash Flow:

$-131.64M

1W Performance:

-5.81%

1M Performance:

+30.39%

6M Performance:

+77.97%

1Y Performance:

+150.33%

1D Range:

$15.38

$16.45

52W Range:

$3.9357

$17.47

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name

Alx Oncology Holdings Inc

Sector

Healthcare (1223)

Industry

Biotechnology (699)

Phone

Address

No. 9 Pembroke Street Upper, Earlsfort Terrace Dublin 2, Dublin

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

ALXO's Discussions on Twitter

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-23	Upgrade	Jefferies	Hold → Buy
Dec-22-21	Downgrade	Jefferies	Buy → Hold
Sep-30-21	Initiated	Stifel	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight
Aug-11-20	Initiated	Credit Suisse	Outperform
Aug-11-20	Initiated	Jefferies	Buy
Aug-11-20	Initiated	Piper Sandler	Overweight

View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday

Benzinga

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Zacks Investment Research

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

Zacks Investment Research

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

GlobeNewswire Inc.

ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer

Benzinga

Alx Oncology Holdings Inc Stock (ALXO) Financials Data

Alx Oncology Holdings Inc (ALXO) Net Income 2024

ALXO net income (TTM) was -$160.81 million for the quarter ending December 31, 2023, a -30.23% decrease year-over-year.

Alx Oncology Holdings Inc (ALXO) Cash Flow 2024

ALXO recorded a free cash flow (TTM) of -$131.64 million for the quarter ending December 31, 2023, a -45.22% decrease year-over-year.

Alx Oncology Holdings Inc (ALXO) Earnings per Share 2024

ALXO earnings per share (TTM) was -$3.74 for the quarter ending December 31, 2023, a -23.43% decline year-over-year.

Alx Oncology Holdings Inc Stock (ALXO) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Sale	14.20	50,000	710,195	604,205
Pons Jaume	PRESIDENT & CSO	Apr 04 '24	Sale	11.15	20,000	223,036	628,359
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Mar 14 '24	Buy	11.31	4,400	49,771	171,620
Pinto Shelly	SVP, Finance and CAO	Jan 04 '24	Sale	13.60	2,717	36,957	78,591
Pons Jaume	President & CSO	Dec 29 '23	Sale	15.04	7,179	107,972	618,359
Randolph Sophia	Chief Medical Officer	Dec 29 '23	Sale	15.04	3,128	47,045	312,349
GARCIA PETER S	Chief Financial Officer	Dec 29 '23	Sale	15.04	1,893	28,471	85,348
Pinto Shelly	SVP, Finance and CAO	Dec 29 '23	Sale	15.04	1,631	24,530	81,308
Pinto Shelly	VP, Finance and CAO	Jul 06 '23	Sale	6.52	7,345	47,889	55,713
Pons Jaume	President & CEO	Jun 30 '23	Sale	7.34	3,208	23,547	536,538

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.